Table 2.

Mortality and immuno-virological status at 5 years (+/−3 months) of children with antiretroviral treatment initiated within the first year of life (ANRS-Pediacam Study, 2008–2013, Cameroon) (N = 149)

			Viral load at 2 years (+/− 3 months) of antiretroviral treatment initiation
	All N = 149		< 4 00 copies/mL N = 90		≥ 400 copies/mL N = 44		Absence of viral load N = 15
	N	%	N	%	N	%	N	%
Death between 2 and 5 years of ART initiation
Yes	5	3.4	0	0.0	2	8.5	3	20.0
No	144	94.6	90	100.0	42	91.5	12	80.0
Virological status at 5 years (+/−3 months) after ART initiation
VL < 400 copies/mL	99	66.4	68	75.6	28	63.6	3	20.0
VL ≥ 400 copies/mL	22	14.8	9	10.0	12	27.3	1	6.7
Absence of VL if not dead at M60	23	15.4	13	14.4	2	4.6	8	53.3
Probability at 5 years (+/−3 months) after ART initiation, using Kaplan-Meier estimation method
Of maintaining virological success (Group 1)	90	64.0 (30 events)
Of achieving at least once VL < 400 copies/mL (Group 2)	44	76.0 (30 events)
CD4 percentage at 5 years of ART initiation
< 15	1	0.7	0	0.0	1	2.3	0	0.0
[15–20[	0	0.0	0	0.0	0	0.0	0	0.0
[20–25[	7	4.7	5	5.6	1	2.3	1	6.7
≥ 25	115	77.2	74	82.2	38	63.6	3	20.0
Not measured if not dead at M60	21	14.1	11	12.2	2	4.6	8	53.3

N: total number of subjects; n: number of subjects in the category; ART antiretroviral therapy; IQR interquartile range; VL viral load; M60 60 months of ART initiation; 95% CI: 95% confidence interval